Rajasthan Recalls Seven Substandard Medicines to Protect Public Health

Key Facts

• Seven medicines recalled in Rajasthan in April 2026 after laboratory testing confirmed they were substandard.
• The recalled medicines include:
  • Cefixime Oral Suspension IP (sold as Loraxim dry syrup)
  • Albendazole tablets (anti-helminthic usage)
  • Istocuf-LS drops (Ambroxol Hydrochloride, Levosalbutamol, Guaifenesin for cough)
  • Methylprednisolone tablets (Methyloactive-4) for inflammation control
  • Okuff-DX syrup for cough relief
  • Cefuroxime Axetil tablets for bacterial infections
  • Ciprofloxacin tablets (broad-spectrum antibiotic)
• The Rajasthan Commissionerate of Food Safety and Drugs Control, led by Drug Controller Ajay Phatak, ordered immediate withdrawal of these medicines from sale, distribution, and use across all pharmacies, hospitals, and supply chains.
• Manufacturing units for these drugs are located in multiple states: Rajasthan, Himachal Pradesh, Delhi, and Uttarakhand.
• Substandard medicines can contain incorrect active ingredient levels or fail quality tests such as assay content and dissolution, leading to treatment failure and serious health risks.
• Substandard antibiotics such as Cefixime, Cefuroxime, and Ciprofloxacin may contribute to the acceleration of antimicrobial resistance (AMR), a serious global public health concern recognized by the World Health Organization.

Background & Context

The Drugs and Cosmetics Act, 1940, governs drug quality monitoring and regulation in India, implemented through state drug control departments coordinated with national pharmaceutical regulations. Regular surveillance, sampling, and testing are essential to ensuring only safe and effective medicines reach the public. The recall action by Rajasthan’s Commissionerate of Food Safety and Drugs Control reflects the state's commitment to upholding medicine quality standards and protecting public health.

Substandard medicines arise from manufacturing deviations including poor ingredient quality, inadequate dosage, or failure to meet pharmacopeial standards. Such medicines not only compromise individual patient outcomes but also exacerbate the wider issue of AMR by allowing bacteria to survive incomplete or ineffective antibiotic treatment.

Why This Matters for Exams / Exam Relevance

This case is significant in understanding the mechanisms of pharmaceutical regulation in India at both state and national levels. It highlights the role of drug regulatory authorities in ensuring medicine quality and the public health risk posed by substandard pharmaceuticals, particularly antibiotics. Awareness of AMR and government efforts to combat it is frequently tested in competitive examinations focused on public health, current affairs, and pharmaceutical policy.

Points to Remember

• Date of recall: April 2026
• Key authority: Ajay Phatak, State Drug Controller, Rajasthan
• Medicines involved: Cefixime, Albendazole, Istocuf-LS, Methylprednisolone, Okuff-DX, Cefuroxime Axetil, Ciprofloxacin
• Manufacturing states: Rajasthan, Himachal Pradesh, Delhi, Uttarakhand
• Risks of substandard medicines: treatment failure, worsening illness, increased antimicrobial resistance
• Regulatory framework: Drugs and Cosmetics Act, state food safety and drugs control commissionerate